cagrisema semaglutide cagrilintide phase 3 results 2024 2025 Comparative Effectiveness of CagriSegma, Semaglutide, and Tirzepatide in the Management of Overweight and Obesity: A Network Meta‐Analysis of Randomized Clinical Trials - Hamarsheh - 2026 - Endocrinology, Diabetes & Metabolism Novo Nordisk presents new Phase

hold grants from Fonds Wetenschappelijk Onderzoek-Vlaanderen (G.0684.12N and G.0830.13N), the Belgian federal government (National Cancer Plan KPC_29_023) and a Concerted Research Action of the KU Leuven (GOA/15/017)

How is Sofwave body skin tightening different from other skin tightening treatments

GLP-1 drugs linked to reduced risk of epilepsy A retrospective analysis of data from adults treated for type-2 diabetes indicates that glucose-lowering GLP-1 drugs could be linked to a lower risk of epilepsy

Fumaric aciduria: an overview and the first Brazilian case report

The Next-generation Obesity Drug Pipeline market was dominated by North America region in 2025 fueled by a robust healthcare system and a high rate of obesity